Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies
- 22 February 2026
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (4) , 1191-1203
Abstract
Gastrointestinal stromal tumors (GISTs), the most common mesenchymal neoplasms of the digestive tract, are primarily driven by gain‐of‐function mutations in the receptor tyrosine kinases KIT or PDGFRA. The introduction of imatinib, a selective tyrosine kinase inhibitor (TKI), revolutionized the management of advanced GIST. However, the emergence of drug resistance remains a major clinical challenge, limiting long‐term efficacy. Resistance mechanisms are multifactorial, predominantly involving secondary mutations in KIT or PDGFRA that impair TKI binding or stabilize the kinase in an active conformation. Beyond genomic alterations, nonmutational adaptive responses—including dysregulation of noncoding RNAs, metabolic reprogramming, epigenetic modifications, and an immunosuppressive tumor microenvironment—significantly contribute to treatment failure. This review comprehensively analyzes these resistance pathways and discusses the evolution of therapeutic strategies toward precision medicine. Current approaches emphasize molecular subtype‐guided first‐line therapy, ctDNA‐driven sequencing of subsequent lines, and the use of novel TKIs (e.g., avapritinib, ripretinib, bezuclastinib) tailored to specific resistance mutations. Furthermore, we explore emerging modalities such as boron neutron capture therapy (BNCT), which offers a kinase‐independent mechanism to target resistant disease, and combination strategies that integrate immunotherapy, epigenetic modulators, and pathway‐specific inhibitors. Advances in liquid biopsy and molecular profiling are enabling real‐time adaptation of therapy, moving GIST management toward a dynamic, personalized paradigm aimed at overcoming resistance and improving patient outcomes.Keywords
This publication has 61 references indexed in Scilit:
- Evaluating boron neutron capture therapy as a potential treatment for unresectable gastrointestinal stromal tumorsGastric Cancer, 2025
- A Review of Genomic Testing and SDH‐ Deficiency in Gastrointestinal Stromal Tumors: Getting to the GISTCancer Medicine, 2025
- Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumoursGastric Cancer, 2023
- Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal TumorsJAMA Oncology, 2021
- Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS StudyThe Oncologist, 2021
- PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumorsClinical and Experimental Medicine, 2018
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in SarcomasJAMA Oncology, 2018
- Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studiesCancer Epidemiology, 2016
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumorsInternational Journal of Cancer, 2009